secwatch / observer
8-K filed March 3, 2026, 6:59 PM ET ticker RNAZ CIK 0001829635
M&A confidence high sentiment positive materiality 0.65

TransCode acquires exclusive license to oncolytic immunotherapy platform in all-stock deal

Transcode Therapeutics, Inc.

item 3.02item 8.01item 3.03item 5.03item 7.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001104659-26-022830
form_type
8-K
ticker
RNAZ
cik
0001829635
company_name
Transcode Therapeutics, Inc.
filed_at
2026-03-03T23:59:59+00:00
discovered_at
2026-05-14T18:02:36.417054+00:00
generated_at
2026-05-15T22:20:02.014947+00:00
sec_items
["3.02", "8.01", "3.03", "5.03", "7.01", "9.01"]
event_type
m_and_a
sentiment
positive
materiality_score
0.65
calibrated_materiality_score
0.65
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001104659-26-022830
json_url
https://secwatch.observer/filing/0001104659-26-022830.json
markdown_url
https://secwatch.observer/filing/0001104659-26-022830.md
text_url
https://secwatch.observer/filing/0001104659-26-022830.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1829635/000110465926022830/0001104659-26-022830-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1829635/000110465926022830/tm267831d1_8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

3ab96d37f9fabd5f7d738c9421b5e54759658ea9

Transcode Therapeutics, Inc.: Filed Certificate of Designation for Series C Non-Voting Convertible Preferred Stock, establishing its preferences, rights, and limitations (effective 2026-03-02).

On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

APAD

Enhanced Group completes de-SPAC merger with Enhanced Ltd; redemptions of $201.7M

Enhanced Group Inc. May 8, 2026, 7:59 PM ET m_and_a Items 1.01, 2.01, 5.06, 3.02, 9.01, 4.01, 3.01, 3.03, 5.01, 5.02, 5.03, 5.05, 7.01

same fact type: governance_change same SEC item: 3.02, 3.03, 5.03, 7.01, 9.01 same event type: m_and_a

This filing

On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware

Comparable filing

As a result of the Business Combination, the Company ceased being a shell company

Filing page SEC filing

PKST

Brookfield completes $1.2B acquisition of Peakstone Realty Trust at $21.00/share

Peakstone Realty Trust May 6, 2026, 7:59 PM ET m_and_a Items 2.01, 3.01, 3.02, 5.03, 3.03, 5.01, 5.02, 8.01, 9.01

same fact type: governance_change same SEC item: 3.02, 3.03, 5.03, 8.01, 9.01 same event type: m_and_a

This filing

On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware

Comparable filing

In addition, at the Company Merger Effective Time, the bylaws of the Company that were in effect immediately prior to the Company Merger Effective Time were amended and restated in their entirety in the form attached hereto as Exhibit 3.2 and became the bylaws of the Surviving Company.

Filing page SEC filing

UHG

Stanley Martin completes $221M all-cash acquisition of United Homes at $1.18/share

United Homes Group, Inc. May 4, 2026, 7:59 PM ET m_and_a Items 1.02, 2.01, 3.01, 3.02, 3.03, 5.03, 5.01, 5.02, 8.01, 9.01

same fact type: governance_change same SEC item: 3.02, 3.03, 5.03, 8.01, 9.01 same event type: m_and_a

This filing

On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware

Comparable filing

Effective upon completion of the Merger, the bylaws of the Company, as in effect immediately prior to the Effective Time, were amended and restated to be in the form of the bylaws filed herewith as Exhibit 3.2.

Filing page SEC filing

GYRE

Gyre Therapeutics completes $300M all-stock acquisition of Cullgen; appoints Ying Luo as CEO

GYRE THERAPEUTICS, INC. May 4, 2026, 7:59 PM ET m_and_a Items 2.01, 5.03, 1.01, 3.02, 3.03, 5.02, 7.01, 9.01

same fact type: governance_change same SEC item: 3.02, 3.03, 5.03, 7.01, 9.01 same event type: m_and_a

This filing

On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware

Comparable filing

The Company has filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock (the “Certificate of Designation”) in connection with the Merger referenced in Item 1.01 above.

Filing page SEC filing

ATER

Aterian sells marquee brands for $18M cash; Lazar to gain ~95% control via $7M preferred stock

Aterian, Inc. April 29, 2026, 7:59 PM ET m_and_a Items 1.01, 3.02, 5.03, 3.03, 5.02, 7.01, 9.01

same fact type: governance_change same SEC item: 3.02, 3.03, 5.03, 7.01, 9.01 same event type: m_and_a

This filing

On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware

Comparable filing

On April 27, 2026, the Company filed a Certificate of Designation of Preferences and Rights of Series AA Convertible Non-Redeemable Preferred Stock of the Company with the Secretary of State of Delaware designating the rights, preferences and limitations of the shares of the Series AA Preferred Stock (the “Series AA Certificate of Designation”).

Filing page SEC filing

Enviri II Corp

New Enviri completes spin-off; starts trading June 2 under NVRI; ~$1.2B revenue, ~$140M EBITDA

Enviri II Corp June 1, 2026, 5:18 PM ET m_and_a Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 7.01, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 7.01, 9.01 same event type: m_and_a

This filing

On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware

Comparable filing

In connection with the Spin-Off, the Board adopted the Code of Conduct, a copy of which is available on New Enviri’s website at www.enviri.com.

Filing page SEC filing

CPRX

Angelini Pharma to acquire Catalyst Pharma for $4.1B ($31.50/share), premium 28% to VWAP

CATALYST PHARMACEUTICALS, INC. May 7, 2026, 7:59 PM ET m_and_a Items 1.01, 5.03, 7.01, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 7.01, 8.01, 9.01 same event type: m_and_a

This filing

On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware

Comparable filing

On May 6, 2026, the Board of Directors approved and adopted an amendment (the “ Forum Selection Amendment ”) to the Company’s existing By-Laws that amends Article VIII, Section 8.1 of the By-Laws of the Company.

Filing page SEC filing

FARM

Farmer Brothers taken private by Royal Cup for $1.29/share; merger closes May 5, 2026

FARMER BROTHERS CO May 5, 2026, 7:59 PM ET m_and_a Items 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 7.01, 9.01 same event type: m_and_a

This filing

On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware

Comparable filing

the Certificate of Incorporation of the Company that was in effect immediately before the Effective Time was amended and restated to be in the form attached hereto as Exhibit 3.1

Filing page SEC filing

Source: SEC EDGAR
accession 0001104659-26-022830
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.